Lefitolimod
As of the edition of 20 October 2026, Lefitolimod is a drug: stopped in 2025; acts on TLR9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Unknown
- Registered trials
- 5, 1 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TLR9 | Toll-like receptor 9 | Q9NR96 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Mologen | Lead sponsor of trials | 2010 to now |